CORRECTING and REPLACING GRAPHIC: Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being
3.6.2019 16:42:00 EEST | Business Wire | Press release
Please replace the graphic with the accompanying corrected graphic on
the release issued May 27, 2019 at 9am BST.
The release reads:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005028/en/
Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire)
SEOUL SEMICONDUCTOR’S SUNLIKE SERIES NATURAL SPECTRUM LEDS SHOWN IN A RECENT STUDY TO HAVE BENEFICIAL EFFECTS ON HUMAN HEALTH AND WELL-BEING
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced the results of a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that the company’s SunLike Series natural spectrum LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K (D65).
In addition to the visual effects of light and lighting on people, such as visual acuity and color fidelity, there are also non-visual effects. These non-visual effects can affect human health and well-being in aspects related to sleep, awakeness, alertness, circadian rhythmicity, circadian disruption, performance, and mood. Recent building standards, such as the ‘WELL Building Standard,’ assess these non-visual effects of lighting in buildings in terms of the ‘melanopic stimulus,’ not just in terms of conventional photometry and colorimetry.
The recent study evaluated the M-EDI (CIE DIS S026/E:2018 Melanopic Equivalent Daylight Illuminance) of different light sources at different correlated color temperatures (CCT in K). M-EDI is the only metric compliant with the International System of Units (IS) to evaluate the non-visual stimulus of light and lighting, based on the CIE (the International Commission on Illumination) D65 standard daylight illuminant. The preliminary results indicate that the SunLike Series natural spectrum LEDs provide more melanopic stimulus, at any given CCT, than any other LED light source at the same photopic illuminance (in lux) – up to 21% more M-EDI stimulus compared to a conventional 4000K CRI80 LED (4000K being the prevalent CCT in office and school environments).
A typical 4000K CRI80 LED provides 59.30 M-EDI lux for every 100 photopic lux, and a 4000K SunLike LED provides 71.94 M-EDI lux at the same photopic illuminance level. At 6500K, the SunLike LED delivers 99.95% of the M-EDI melanopic stimulus provided by the CIE D65 daylight standard illuminant at the same photopic illuminance. It means that at 6500K, the SunLike Series LEDs provide the same natural melanopic stimulus as daylight (D65).
The reason for this is that the SunLike Series natural spectrum LEDs have a continuous spectral power distribution (SPD) emission that mimics sunlight spectrum at different CCT, in the visual region not including UV and IR. Conventional LED light sources have a peak at 450nm, followed by a valley at the peak of the melanopic efficiency curve, around 480nm. This peak at 450nm for conventional LEDs may also produce non-desired effects on eye health. The melanopic stimulus of the 6500K SunLike LEDs match the shape of the melanopic stimulus provided by D65, avoiding potential blue light peak and ethical issues.
Human centric lighting solutions go beyond the prevalent visual metrics of photometry colorimetry and conventional lighting design. The SunLike Series natural spectrum LEDs offer better visual appearance and color fidelity (CRI95+), and are specifically designed and engineered to provide more benefits and energy for human health and well-being than any other LED in the marketplace. SunLike Series LEDs are the light source of choice for integrative lighting solutions.
Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight. It has also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.
SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology, which defines its original concept as “the light closest to the sun for human well-being.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source. TRI-R is a registered trademark of Toshiba Material Co., Ltd.
The left figure is how the melanopic stimulus of commercial LEDs increases and the right figure shows the same results by family of LEDs. SunLike LEDs provide more melanopic stimulus than the other LEDs (study under publication).
# # #
About Dr. Octavio L. Perez
Dr. Octavio L. Perez is a
passionate professional and scholar who contributes to exploring,
developing and bringing to the real world the benefits of light and
lighting for human wellbeing and wellness, and ultimately health,
integrating in this vision the traditional visual and aesthetical
principles of lighting, altogether with energy savings and
sustainability values. He works internationally as an independent
consultant, focused in human centric lighting (HCL), more precisely
“affective lighting”. He is also an adjunct researcher at Mount Sinai
Hospital in NYC, where he completed his doctoral research with funding
from NIH (National Institutes of Health).
About Seoul Semiconductor
Seoul Semiconductor develops and
commercializes LEDs for automotive, general illumination, specialty
lighting, and backlighting markets. As the second-largest LED
manufacturer globally excluding the captive market, Seoul Semiconductor
holds more than 14,000 patents, offers a wide range of technologies, and
mass produces innovative LED products such as SunLike – delivering the
world’s best light quality in a next-generation LED enabling
human-centric lighting optimized for circadian rhythms; WICOP – a
simpler structured package-free LED which provides market leading color
uniformity and cost savings at the fixture level, providing high lumen
density and design flexibility; NanoDriver Series – the world’s smallest
24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED
technology developed in 2005, including all AC LED-related technologies
from chip to module and circuit fabrication, and nPola, a new LED
product based on GaN-substrate technology that achieves more than ten
times the output of conventional LEDs. UCD constitutes a high color
gamut display which delivers more than 90% NTSC. For more information,
please visit www.seoulsemicon.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005028/en/
Contact information
Seoul Semiconductor Inc.
Jeonghee Kim
Tel:
+82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
